Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Abbott Laboratories, decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Return on Assets (ROA)
The Return on Assets demonstrates an initial upward trend from 6.2% in 2020 to 9.4% in 2021, followed by a slight decrease to 9.31% in 2022 and a further decline to 7.82% in 2023. Notably, there is a significant increase to 16.46% in 2024, indicating improved efficiency in utilizing assets to generate profit in the most recent period.
Financial Leverage
Financial leverage shows a consistent downward trend over the period, decreasing from 2.21 in 2020 to 1.71 in 2024. This suggests a gradual reduction in the use of debt relative to equity, potentially lowering financial risk and indicating a strengthening equity base over time.
Return on Equity (ROE)
Return on Equity increases sharply from 13.71% in 2020 to 19.75% in 2021. It then slightly declines to 18.9% in 2022 and further to 14.83% in 2023 before experiencing a substantial rise to 28.12% in 2024. This pattern reflects variability in profitability and the company's ability to generate returns for shareholders, with the most recent year showing a marked improvement.

Three-Component Disaggregation of ROE

Abbott Laboratories, decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The analysis of the financial performance over the given periods reveals several key trends in profitability, efficiency, leverage, and overall return on equity.

Net Profit Margin
The net profit margin exhibited a general upward trend with some fluctuations. Beginning at 12.99% in 2020, it increased to a peak of 16.42% in 2021, then slightly declined over the next two years to 14.27% in 2023. A significant surge is observed in 2024, with the margin reaching 31.95%, more than doubling the previous year's figure. This indicates a substantial improvement in profitability in the most recent year.
Asset Turnover
Asset turnover ratio showed moderate variation throughout the period. Starting at 0.48 in 2020, it increased to 0.59 by 2022, reflecting improved efficiency in using assets to generate sales. However, this ratio declined slightly to 0.55 in 2023 and further to 0.52 in 2024, suggesting a modest reduction in asset utilization effectiveness in the last two years.
Financial Leverage
The financial leverage ratio consistently decreased over the reviewed timeframe, moving downward from 2.21 in 2020 to 1.71 in 2024. This trend indicates a conscious reduction in reliance on debt financing relative to equity, suggesting a more conservative capital structure and potentially lower financial risk.
Return on Equity (ROE)
ROE closely mirrored the pattern observed in net profit margin but with less volatility. Starting at 13.71% in 2020, ROE peaked at 19.75% in 2021, then dipped to 14.83% in 2023 before a pronounced increase to 28.12% in 2024. The strong ROE growth in 2024 indicates improved overall profitability for shareholders, likely driven by the higher net profit margin combined with changes in asset efficiency and leverage.

Five-Component Disaggregation of ROE

Abbott Laboratories, decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Tax Burden
From 2020 to 2023, the tax burden ratio demonstrated a gradual decline, moving from 0.9 down to 0.86 and further dropping to 0.83 in 2022 before slightly recovering to 0.86 in 2023. However, there was a significant and abrupt increase to 1.91 in 2024, indicating a considerable change in the company's effective tax rate or related adjustments in that year.
Interest Burden
The interest burden ratio remained relatively stable over the five-year period, fluctuating within a narrow range between 0.9 and 0.94. This consistency suggests steady interest expenses relative to earnings before interest and taxes across the years.
EBIT Margin
The EBIT margin showed an improving trend from 16% in 2020 to over 20% in 2021 and 2022, reflecting enhanced operational efficiency or profitability at the EBIT level. Nevertheless, it declined in subsequent years, falling to 18.2% in 2023 and slightly lower to 18.05% in 2024, indicating some pressure on operating earnings or increased costs impacting margins.
Asset Turnover
Asset turnover experienced growth from 0.48 in 2020 to a peak of 0.59 in 2022, suggesting improved efficiency in using assets to generate sales. After 2022, it diminished gradually to 0.55 in 2023 and 0.52 in 2024, implying a slight decrease in the asset utilization effectiveness.
Financial Leverage
Financial leverage steadily decreased over the period, moving from 2.21 in 2020 down to 1.71 in 2024. This denotes a reduction in the use of debt financing relative to equity, suggesting an overall de-leveraging trend or a strengthening equity base within the capital structure.
Return on Equity (ROE)
ROE increased from 13.71% in 2020 to a peak of 19.75% in 2021, followed by a slight dip to 18.9% in 2022 and a more notable decrease to 14.83% in 2023. In 2024, ROE experienced a marked increase to 28.12%. This volatility may be linked to variations in profitability, leverage, or other operational factors, with the sharp rise in 2024 indicating a substantial enhancement in overall equity returns.

Two-Component Disaggregation of ROA

Abbott Laboratories, decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2024 = ×
Dec 31, 2023 = ×
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Net Profit Margin
The net profit margin exhibited a steady increase from 12.99% in 2020 to a peak of 16.42% in 2021, followed by a slight decline over the next two years to 14.27% in 2023. However, there is a notable and significant surge in 2024, where the net profit margin jumps sharply to 31.95%, indicating a substantial improvement in profitability during that year.
Asset Turnover
Asset turnover showed a gradual upward trend from 0.48 in 2020 to 0.59 in 2022, suggesting improved efficiency in using assets to generate sales. This trend reversed slightly after 2022, declining to 0.55 in 2023 and further to 0.52 in 2024, indicating a marginal reduction in asset utilization efficiency in the latter years.
Return on Assets (ROA)
The return on assets followed a pattern somewhat similar to net profit margin. It rose significantly from 6.2% in 2020 to 9.4% in 2021 and remained relatively stable at 9.31% in 2022. In 2023, ROA decreased to 7.82%, before experiencing a strong increase to 16.46% in 2024, reflecting enhanced overall profitability relative to asset base in the most recent year.
Overall Observations
Both profitability ratios, net profit margin and return on assets, demonstrate strong improvement in 2024 after a period of moderate fluctuation. The increase in profitability metrics is substantial, suggesting either improved cost management, product mix, pricing strategies, or other operational factors positively influencing earnings. Meanwhile, the asset turnover ratio's slight decline in the latter years may indicate that despite improved profitability, asset utilization efficiency has decreased marginally. This divergence could imply that profitability gains are not primarily driven by asset efficiency but possibly by higher margins or exceptional gains.

Four-Component Disaggregation of ROA

Abbott Laboratories, decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Dec 31, 2020 = × × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Tax Burden
The tax burden ratio shows a decreasing trend from 0.9 in 2020 to 0.83 in 2022, indicating a lower portion of earnings paid as taxes during this period. However, it slightly increased to 0.86 in 2023 before sharply rising to 1.91 in 2024. This substantial increase in 2024 suggests an unusual tax scenario or potential accounting adjustment impacting net income significantly.
Interest Burden
The interest burden ratio remains relatively stable throughout the five years, fluctuating slightly between 0.90 and 0.94. This stability implies consistent interest expense management relative to earnings before interest and taxes (EBIT) over time.
EBIT Margin
The EBIT margin improved from 16% in 2020 to above 20% in 2021 and 2022, reflecting improved operating profitability. Nonetheless, it declined to around 18.2% in 2023 and marginally decreased further to 18.05% in 2024, indicating some erosion in operating efficiency or increased costs in the recent years.
Asset Turnover
Asset turnover ratio increased steadily from 0.48 in 2020 to 0.59 in 2022, showing more effective use of assets to generate sales. It then declined to 0.55 in 2023 and further to 0.52 in 2024, suggesting a modest reduction in the efficiency of asset utilization in the latter years.
Return on Assets (ROA)
The ROA improved markedly from 6.2% in 2020 to approximately 9.4% in 2021 and 9.31% in 2022, indicating enhanced overall profitability relative to assets. It dipped to 7.82% in 2023 but surged dramatically to 16.46% in 2024. This spike likely reflects either exceptional performance, changes in tax or interest expenses, or other factors influencing net income and asset base profitability.

Disaggregation of Net Profit Margin

Abbott Laboratories, decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Tax Burden
The tax burden ratio displayed a declining trend from 0.9 in 2020 to a low of 0.83 in 2022, indicating a decreasing portion of earnings consumed by taxes during this period. However, there was a slight increase to 0.86 in 2023, followed by a significant surge to 1.91 in 2024, suggesting an unusual tax event or accounting adjustment markedly increasing tax expenses relative to pre-tax earnings in the latest year.
Interest Burden
The interest burden ratio remained relatively stable and favorable, fluctuating narrowly between 0.9 and 0.94 from 2020 to 2024. This stability indicates consistent management of interest expenses relative to earnings before interest and taxes, reflecting steady financial leverage and cost of debt over the five-year period.
EBIT Margin
The EBIT margin demonstrated improvement from 16% in 2020 to above 20% in both 2021 and 2022, showing enhanced operational profitability during these years. However, the margin declined to 18.2% in 2023 and slightly further to 18.05% in 2024, signaling a reduction in operating efficiency or increased operating costs after the peak years.
Net Profit Margin
The net profit margin exhibited overall growth with some volatility. It rose from 12.99% in 2020 to 16.42% in 2021, then slightly decreased to 15.88% in 2022, followed by a further decline to 14.27% in 2023. In 2024, there was a pronounced increase to 31.95%, which more than doubled the prior year’s margin. This sharp rise could indicate extraordinary gains, cost reductions, or a one-time event affecting net profitability.